3,4-dihydroxyphenylacetic acid has been researched along with Movement Disorders in 20 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
Excerpt | Relevance | Reference |
---|---|---|
"Two cases of severe dystonia and dyskinesia were treated with talipexole, a dopamine autoreceptor agonist, and the metabolites of dopamine, norepinephrine, and serotonin in cerebrospinal fluid (CSF) were determined." | 3.68 | Chronic treatment with talipexole dihydrochloride on abnormal involuntary movement in humans. ( Koga, I; Nishikawa, T; Tanaka, M; Tsuda, A; Uchida, Y; Yamada, S, 1990) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (30.00) | 18.7374 |
1990's | 5 (25.00) | 18.2507 |
2000's | 5 (25.00) | 29.6817 |
2010's | 4 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ngwa, HA | 1 |
Kanthasamy, A | 1 |
Jin, H | 1 |
Anantharam, V | 1 |
Kanthasamy, AG | 1 |
Masoud, ST | 1 |
Vecchio, LM | 1 |
Bergeron, Y | 1 |
Hossain, MM | 1 |
Nguyen, LT | 1 |
Bermejo, MK | 1 |
Kile, B | 1 |
Sotnikova, TD | 1 |
Siesser, WB | 1 |
Gainetdinov, RR | 1 |
Wightman, RM | 1 |
Caron, MG | 1 |
Richardson, JR | 1 |
Miller, GW | 1 |
Ramsey, AJ | 1 |
Cyr, M | 1 |
Salahpour, A | 1 |
Willard, AM | 1 |
Bouchard, RS | 1 |
Gittis, AH | 1 |
Morelli, E | 1 |
Moore, H | 1 |
Rebello, TJ | 1 |
Gray, N | 1 |
Steele, K | 1 |
Esposito, E | 1 |
Gingrich, JA | 1 |
Ansorge, MS | 1 |
Kato, H | 1 |
Kurosaki, R | 1 |
Oki, C | 1 |
Araki, T | 1 |
de Lago, E | 1 |
Fernández-Ruiz, J | 1 |
Ortega-Gutiérrez, S | 1 |
Cabranes, A | 1 |
Pryce, G | 1 |
Baker, D | 1 |
López-Rodríguez, M | 1 |
Ramos, JA | 1 |
Jeste, DV | 1 |
Doongaji, DR | 1 |
Linnoila, M | 1 |
Kontur, PJ | 1 |
al-Tikriti, M | 1 |
Innis, RB | 1 |
Roth, RH | 1 |
Campbell, JM | 1 |
Gilmore, DP | 1 |
Russell, D | 1 |
Growney, CA | 1 |
Favor, G | 1 |
Weir, J | 1 |
Stone, TW | 1 |
Payne, AP | 1 |
Paul, G | 1 |
Reum, T | 1 |
Meissner, W | 1 |
Marburger, A | 1 |
Sohr, R | 1 |
Morgenstern, R | 1 |
Kupsch, A | 1 |
Hyland, K | 1 |
Beaman, BL | 1 |
LeWitt, PA | 1 |
DeMaggio, AJ | 1 |
Campbell, BM | 1 |
Gresch, PJ | 1 |
Walker, PD | 1 |
Nishikawa, T | 1 |
Yamada, S | 1 |
Tsuda, A | 1 |
Tanaka, M | 1 |
Koga, I | 1 |
Uchida, Y | 1 |
Dávila, R | 1 |
Andía, I | 1 |
Miller, JC | 1 |
Friedhoff, AJ | 1 |
Guimón, J | 1 |
Apicella, P | 1 |
Trouche, E | 1 |
Nieoullon, A | 1 |
Legallet, E | 1 |
Dusticier, N | 1 |
Bradbury, AJ | 2 |
Costall, B | 2 |
Domeney, AM | 2 |
Testa, B | 1 |
Jenner, PG | 1 |
Marsden, CD | 2 |
Naylor, RJ | 2 |
Jenner, PJ | 1 |
Kostic, V | 1 |
Djuricic, B | 1 |
Paschen, W | 1 |
Cross, AJ | 1 |
Crow, TJ | 1 |
Ferrier, IN | 1 |
Johnson, JA | 1 |
Johnstone, EC | 1 |
Owen, F | 1 |
Owens, DG | 1 |
Poulter, M | 1 |
Bourke, CA | 1 |
20 other studies available for 3,4-dihydroxyphenylacetic acid and Movement Disorders
Article | Year |
---|---|
Vanadium exposure induces olfactory dysfunction in an animal model of metal neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Animals; Disease Models, Animal; Dopamin | 2014 |
Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Dyskinesia Agents; Cell Death; Cytosol; Dopamine; Dopa | 2015 |
Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Chromatography, High Pressure Liquid; Di | 2015 |
Chronic 5-HT transporter blockade reduces DA signaling to elicit basal ganglia dysfunction.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Animals, Newborn; Basal Ganglia; Cell Count; C | 2011 |
Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Caprylates; Cell Communication; Dopamine; Glial | 2004 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Elevated cerebrospinal fluid noradrenaline in tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Homovan | 1984 |
Postmortem stability of monoamines, their metabolites, and receptor binding in rat brain regions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Brain; Brain Chemistry; Dopamine; Huma | 1994 |
Extracellular levels of dopamine and its metabolite 3,4-dihydroxy-phenylacetic acid measured by microdialysis in the corpus striatum of conscious AS/AGU mutant rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Extracellular Space; Male; Micro | 1998 |
High frequency stimulation of the subthalamic nucleus influences striatal dopaminergic metabolism in the naive rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Electric Stimulation; Extracellu | 2000 |
Monoamine changes in the brain of BALB/c mice following sub-lethal infection with Nocardia asteroides (GUH-2).
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Brain; Cerebellum; Dopamine; Female; H | 2000 |
Neonatal dopamine depletion reveals a synergistic mechanism of mRNA regulation that is mediated by dopamine(D1) and serotonin(2) receptors and is targeted to tachykinin neurons of the dorsomedial striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Animals, Newborn; Dopamine; Dopamine Agonists; Dopam | 2001 |
Chronic treatment with talipexole dihydrochloride on abnormal involuntary movement in humans.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Azepines; Dopamine Agents; Dystonia; Homovanillic Acid; Humans | 1990 |
Evidence of low dopaminergic activity in elderly women with spontaneous orofacial dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Dopamine; Estradiol; Facial Muscles; Female | 1991 |
Motor impairments and neurochemical changes after unilateral 6-hydroxydopamine lesion of the nigrostriatal dopaminergic system in monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Choline O-Acetyltransferase; Corpus Striatum; Dopami | 1990 |
The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 1985 |
The neurotoxic actions of 6-hydroxydopamine infused into the rat substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 1986 |
Hemiballismus: changes in cerebrospinal fluid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Dominance, Cerebral; Dopamine; Female; Homovanillic Acid; Huma | 1988 |
Chemical and structural changes in the brain in patients with movement disorder.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Antipsychotic Agents; Brain; Choline O-Acetyltransfer | 1985 |
A novel nigrostriatal dopaminergic disorder in sheep affected by Tribulus terrestris staggers.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Efferent Pathways; Female; Levod | 1987 |